Mass Drug Administration of Azithromycin to Reduce Child Mortality: Only for High-Mortality Settings?
Am J Trop Med Hyg
.
2020 Sep;103(3):1274-1275.
doi: 10.4269/ajtmh.19-0071.
Authors
Kirkby D Tickell
1
2
3
,
Emily L Deichsel
4
,
Judd L Walson
5
1
6
3
2
Affiliations
1
The Childhood Acute Illness and Nutrition (CHAIN) Network, Nairobi, Kenya.
2
Department of Global Health, University of Washington, Seattle, Washington.
3
Department of Epidemiology, University of Washington, Seattle, Washington.
4
Center for Vaccine Development for Global Health, University of Maryland School of Medicine, Baltimore, Maryland.
5
Department of Medicine (Infectious Disease), University of Washington, Seattle, Washington.
6
Department of Pediatrics, University of Washington, Seattle, Washington.
PMID:
30734698
PMCID:
PMC7470569
DOI:
10.4269/ajtmh.19-0071
No abstract available
MeSH terms
Anti-Bacterial Agents / administration & dosage*
Azithromycin / administration & dosage*
Child
Child Mortality*
Global Health
Humans
Mass Drug Administration
Substances
Anti-Bacterial Agents
Azithromycin
Grants and funding
T32 AI007524/AI/NIAID NIH HHS/United States